Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05157165 Available - COVID-19 Clinical Trials

Convalescent Plasma in Hospitalized COVID-19 Patients

Start date: n/a
Phase:
Study type: Expanded Access

The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.

NCT ID: NCT04657458 Available - Covid19 Clinical Trials

A Global Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS

Start date: n/a
Phase:
Study type: Expanded Access

Infusion Treatment Using Bone Marrow Mesenchymal Stem Cell (bmMSC) Derived Extracellular Vesicle Product, ExoFlo™, for COVID-19 Associated ARDS (EXIT COVID-19), is currently being studied in Protocol DB-EF-PhaseII-001 in patients with COVID-19 associated moderate to severe Acute Respiratory Distress Syndrome (ARDS). This expanded access protocol is an open-label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase II randomized controlled trial because they: - Do not meet phase II eligibility criteria at current phase II sites. - Do meet phase II eligibility criteria but cannot access phase II sites. - Do not meet phase II eligibility criteria & cannot access phase II sites. •

NCT ID: NCT04657406 Available - Covid19 Clinical Trials

Expanded Access to Zofin for Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

NCT ID: NCT04646031 Available - Covid19 Clinical Trials

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening condition.

NCT ID: NCT04617535 Available - COVID-19 Clinical Trials

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

NCT ID: NCT04456439 Available - Clinical trials for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

NCT ID: NCT04445207 Available - COVID Clinical Trials

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.

NCT ID: NCT04420988 Available - COVID-19 Clinical Trials

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19.